These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28241944)

  • 1. Cerebrovascular events as presenting manifestations of Myeloproliferative Neoplasm.
    Ong E; Barraco F; Nighoghossian N; Praire A; Desestret V; Derex L; Vighetto A; Biotti D
    Rev Neurol (Paris); 2016 Nov; 172(11):703-708. PubMed ID: 28241944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms.
    Stefanou MI; Richter H; Härtig F; Wang Y; Örgel A; Bender B; Mengel A; Ziemann U; Poli S
    Eur J Neurol; 2019 Jun; 26(6):903-e64. PubMed ID: 30629793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
    Mahjoub S; Baccouche H; Sahnoun M; Kaabi H; Manai Z; Slama H; Ben Romdhane N
    Tunis Med; 2015 Jul; 93(7):474-7. PubMed ID: 26757507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms.
    Enblom A; Lindskog E; Hasselbalch H; Hersby D; Bak M; Tetu J; Girodon F; Andréasson B
    Eur J Intern Med; 2015 Jun; 26(5):344-7. PubMed ID: 25863408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
    Fourgeaud C; El Nemer W; Michon Pasturel U; Bonhomme S; Brignier A; Lazareth I; Priollet P
    J Mal Vasc; 2015 Dec; 40(6):350-8. PubMed ID: 26362408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
    Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
    Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Andıç N; Ünübol M; Yağcı E; Akay OM; Yavaşoğlu İ; Kadıköylü VG; Bolaman AZ
    Turk J Haematol; 2016 Sep; 33(3):187-95. PubMed ID: 27094255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Analysis of 208 Patiets with BCR/ABL Negative Myeloproliferative Neoplasms].
    Shen QH; Guo YJ; Xue CE; Wang Y; Lin FR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):159-164. PubMed ID: 30738463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.
    Strati P; Bose P; Lyle L; Gaw K; Zhou L; Pierce SA; Huynh-Lu J; Hirsch-Ginsberg CF; Bueso-Mendoza DE; Bueso-Ramos CE; Verstovsek S
    Ann Hematol; 2017 May; 96(5):733-738. PubMed ID: 28247057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
    Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
    Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
    BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical Characteristics of Patients with JAK2 Gene Mutation Myeloproliferative Neoplasms].
    Li YJ; Zhu SR; Liu WY; Ming J; Wang ZQ; Zhang SS; Hu XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1533-1539. PubMed ID: 34627436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.